The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice

被引：0
|
作者：
Yorifuji, Naoki
Inoue, Takuya
Fujiwara, Kaori
Iguchi, Munetaka
Kojima, Yuichi
Okada, Toshihiko
Kakimoto, Kazuki
Nouda, Sadaharu
Kawakami, Ken
Abe, Yosuke
Takeuchi, Toshihisa
Higuchi, Kazuhide
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su2023
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [31] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Carolyn F. Deacon
    Jens J. Holst
    Advances in Therapy, 2009, 26 : 488 - 499
  • [32] Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Johnson, Kathryn M. S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (04) : 455 - 463
  • [33] Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Miller, Shannon A.
    St. Onge, Erin L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1336 - 1343
  • [34] A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients
    Terasaki, Michishige
    Hiromura, Munenori
    Mori, Yusaku
    Kohashi, Kyoko
    Kushima, Hideki
    Koshibu, Masakazu
    Saito, Tomomi
    Yashima, Hironori
    Watanabe, Takuya
    Hirano, Tsutomu
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2018, 2018
  • [35] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [36] Dipeptidyl peptidase-4 inhibitor (sitagliptin) improves insulin sensitivity and atherosclerosis-related biomarkers in patients with type 2 diabetes
    Yamane, T.
    Suzuki, Y.
    Iwai, R.
    Sakuma, Y.
    Yoshida, S.
    Hashimoto, N.
    DIABETOLOGIA, 2012, 55 : S323 - S323
  • [37] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Indomethacin-Induced Intestinal Mucosal Injury in a Model of Type 2 Diabetes
    Yorifuji, Naoki
    Inoue, Takuya
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S790 - S790
  • [38] Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes
    Odawara M.
    Kadowaki T.
    Tajima N.
    Nishii M.
    Taniguchi T.
    Ferreira J.C.A.
    Diabetology International, 2011, 2 (2) : 94 - 105
  • [39] Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
    Herman, Gary A.
    Bergman, Arthur
    Yi, Bingming
    Kipnes, Mark
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 1939 - 1947
  • [40] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved β cell function in patients with type 2 diabetes:: a model-based analysis
    Xu, L.
    Dalla Man, C.
    Cobelli, C.
    Williams-Herman, D.
    Meininger, G.
    Khatami, H.
    Stein, P.
    DIABETOLOGIA, 2006, 49 : 396 - 397
12345